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Abstract
In 2015 the United Kingdom (UK) became the first nation to legalize egg and zygotic nuclear transfer pro-
cedures using mitochondrial replacement techniques (MRTs) to prevent the maternal transmission of serious
mitochondrial DNA diseases to offspring. These techniques are a form of human germline genetic modification
and can happen intentionally if female embryos are selected during the MRT clinical process, either through
sperm selection or preimplantation genetic diagnosis (PGD). In the same year, an MRT was performed by a
United States (U.S.)-based physician team. This experiment involved a cross-border effort: the MRT procedure
per se was carried out in the US, and the embryo transfer in Mexico. The authors examine the ethics of MRTs
from the standpoint of genetic relatedness and gender implications, in places that lack adequate laws and
regulation regarding assisted reproduction. Then, we briefly examine whether MRTs can be justified as a
reproductive option in the US and Mexico, after reassessing their legalization in the UK. We contend that
morally inadequate and ineffective regulations regarding egg donation, PGD, and germline genetic modifica-
tions jeopardize the ethical acceptability of the implementation of MRTs, suggesting that MRTs are currently
difficult to justify in the US and Mexico. In addition to relevant regulation, the initiation and appropriate use of
MRTs in a country require a child-centered follow-up policy and more evidence for its safety.
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Introduction
Human cells harbor two different types of genomes.Inside the cells, more than 99.9% of DNA is localized in
the nucleus, whereas the remaining 0.1% of DNA exists in
mitochondria (termed nDNA and mtDNA, respectively). Mi-
tochondrial functions are exerted through the coordinate ex-
pression of genes in the dual genomes of nDNA and mtDNA.1
The most important function of the mitochondrion is proba-
bly the respiratory chain, by which cellular energy, adenosine
triphosphate (ATP), is produced while precisely regulating
the leakage of deleterious free radicals. To date, 13 mtDNA-
encoded and 228 nDNA-encoded genes have been linked with
the onset of mitochondrial DNA diseases (mtDNA diseases) in
humans when mutated.2 A human egg (oocyte) has as many as
200,000–300,000 copies of mtDNA per cell.1 Because paternal
mitochondria are digested after fertilization, wild-type or mu-
tated mtDNA is maternally inherited to offspring, with at least
30 different mtDNA haplotypes.3
At present, mitochondrial replacement techniques (MRTs)
are experimental nuclear transfer procedures where donor
oocytes are used to reconstitute oocytes or zygotes with a
reduced mtDNAmutation load. Briefly, the nuclear transfer is
carried out between the affected intended mother’s oocyte and
an unaffected donor’s oocyte (maternal spindle transfer;
MST)4–6 or between the intended parents’ derived zygote and
a donor zygote or a zygote created fertilizing a donor oocyte
with a spermatozoon from the intended father (pronuclear
transfer; PNT).7,8 In October 2015, the United Kingdom (UK)
became the first country to legalize MRTs to prevent the ma-
ternal transmission of serious mtDNA diseases to offspring, in
instances where alternatives such as preimplantation genetic
diagnosis (PGD) are clinically inapplicable.9
Around the same time as the legalization of MRTs took
place in the UK, a group led by Dr. John Zhang, a fertility
expert, performed MST for preventing a mitochondrial dis-
ease at their clinic in New York, and then shipped the only
euploid embryo (of five created) to their affiliated clinic in
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Guadalajara, Mexico.6 This experiment resulted in the birth
of a, so far, healthy boy. The parents, who seemed to have
been insufficiently informed of potential risks of MST,
decided to heavily limit follow-up examination of their
child.10 The cross-border nature of this experiment suggests
the likelihood that scientists might try to break down the
MRT procedure in such a way that it does not violate any
local laws or regulations, even when the procedure as a
whole might be banned in such places.11,12
MRTs raise a number of important ethical issues. First,
although MRTs may offer a new reproductive opportunity
for some women to have genetically related and unaffected
children, the resultant children have mtDNA derived from
an egg donor in addition to nDNA from parents, prompting
the possibility of such children having three genetic parents.
However, at this point in time it is uncertain how society
will perceive this third genetic contributor. Second, MRTs
have unique gender implications for the resultant children
and oocyte donors. As MRTs remain experimental and
subject to human technical dexterity,4,5,7,8 their clinical use
might fail to prevent the maternal transmission of an mtDNA
disease. Third, MRTs can result in a form of human germline
genetic modification that has been viewed as taboo in many
countries.13,14 Notably, a report by the US National Acade-
mies of Sciences (NAS) proposed a policy of transferring
only male embryos in initial MRTs to prevent the occurrence
of transgenerational risks.15 Can such an embryo transfer
policy truly justify the clinical use of MRTs? Finally, the
implementation of MRTs requires oocyte donation, with its
accompanying socioethical implications, as well as physical
burdens and possibly health risks to egg donors.13 The
present article interrogates the ethics of MRT primarily from
the standpoint of genetic relatedness and gender implica-
tions. Then, it analyzes whether MRTs can be justified in the
US and Mexico, after reexamining the legalization in the UK
after reexamining the legalization in the UK.
Genetic Relatedness
Women who have a pathogenic mtDNA mutation in their
oocytes and who want to have genetically related children
undergo a dire fate that deserves our sympathy. Sharon Ber-
nardi is a living witness: She lost all seven of her children due
to mitochondrial disease.16 In the UK, MRTs legally offer a
new reproductive opportunity for such women to have unaf-
fected children who are genetically related to them, if there are
no effective clinical alternatives. This effectively means that
the reproductive freedom of such women is expanded. This
benefit to intended mothers should not be confused with the
supposed therapeutic benefit for living mitochondrial disease
sufferers, which has been shown to be nonexistent.17,18
In addition to expanding the reproductive freedom of
women wanting genetically related and healthy children, the
genetic relatedness formed through MRTs must be also in-
terrogated from the child’s standpoint. MRTs introduce a new
twist to the traditional academic debate regarding third party
reproduction (i.e., using egg or sperm donors). In this study
not only the assistance of a donor oocyte is essential but also
it opens the important question of how many parents have
children produced by MRTs. Consider, for example, how
Alana Saarinen, 1 of 17 children born after donor ooplasmic
transfer in the US, self-reports how she regards the person
who provided the cytoplasm with which her mother’s egg
was ‘‘augmented.’’ Let us remember that in oocyte-
cytoplasmic transfer cytoplasm from a donated oocyte is
ferried into the intending mother’s egg to make up for a
presumptive ‘‘ooplasmic deficiency.’’19 Alana said: ‘‘I also
have DNA from a third lady. But I wouldn’t consider her a
third parent.’’20 Her perception could be based on the fact that
mtDNA accounts for only 0.1% of DNA in human cells and
that mtDNA encodes only 13 respiratory chain proteins.21
It is possible that parents of children born from MRTs
might consider that the ‘‘genetic integrity’’ of their children
is equivalent to that of ‘‘normally produced ones’’ and, thus,
that they only have two genetic parents. However, this
would be a mistake since children who are a product of
MRTs do have three genetic parents, contrary to what the
Nuffield Council on Bioethics, the UK’s Department of
Health, and the UK’s Human Fertilisation and Embryology
Authority have asserted. We can defend the claim that such
children have three genetic parents in the following way.
The amount of mtDNA cannot be used as an argument
against egg donors being genetic parents. To understand
this, consider the following thought experiment: a scientist
takes 1% of nDNA from 100 people and fuses it together,
creating a healthy child. In this study we would say that such
a child has 100 genetic parents. If this is true then we could
further imagine the same scenario, but where the percentage
of taken nDNA is 0.1% (the same percentage as that of
mtDNA) from 1000 people. If it is true that this child has
1000 genetic parents, no matter how wild this sounds, then
we have to accept that the egg donor in MRT scenarios is a
genetic parent too.22 One might rebut that mtDNA, which
contributes to only 0.1% in human genome, as such, does
not play a significant role in genetic parenthood. However, if
we think that only the transfer of genetic material that
confers ‘‘personal characteristics’’ establishes genetic par-
enthood then we have to accept that egg donors in MRT
cases are genetic parents. They are so because the mito-
chondria, contained in the donated enucleated eggs, are a
fundamental piece in ‘‘conferring’’ health, which is a per-
sonal characteristic.
Children born from MRTs are different from children born
following infertility treatment using donor gametes in terms of
the genetic parenthood uniquely formed by the MRT. Unlike
Alana, some children born from MRTs might acknowledge
egg donors as genetic parents, demanding from them what
is legally and morally required from egg and sperm donors.
Furthermore, this novel genetic composition opens the
question of whether or not clinics should offer counseling
services to such children as part of the follow-up treatment.
Gender Implications
MRTs have other specific gender implications for the
resultant children and oocyte donors. Let us begin with the
gender implications of MRTs, as the Genetic Relatedness
section calls for great insight from the standpoint of the
resultant children. It is a truism that there is no medicine
without risks, and MRTs are not the exception. MRTs might
fail to prevent the maternal transmission of a pathogenic
mtDNA mutation to the resultant offspring.4,5,7,8 Further-
more, even if children born after MRTs do not develop life-
threatening disease, some females might undergo the same
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fate as their mothers: they could be at risk of transmitting a
mtDNA disease to their future children (just as women who
are not affected by a mtDNA disease but who have a
pathogenic mtDNA mutation in their oocytes). For this, and
to avoid ‘‘crossing the germline,’’ a report by the US NAS
proposed a policy of transferring only male embryos in
initial MRTs.15 This, according to them, would avoid im-
posing harms to subsequent generations. Seemingly, this
policy could be compared with the use of PGD to avoid sex-
linked diseases by selecting embryos of a particular chro-
mosomal sex.23 In PGD a cell from a cleaving embryo,
or blastocyst, is harvested to perform a genetic analysis.
However, the selection of male embryos through PGD after
an MRT, when this was not done through sperm sorting,
requires an additional invasive procedure24 (in addition to
the nuclear transfer) which reduces the overall number of
potential embryos for transfer (i.e., female embryos are se-
lected against), and which could lead to implantation loss.25
Moreover, it is unknown if the combined use of MRT and
PGD might increase the risk that offspring are born with an
impairment, which would clearly go against the intended
mother’s, or couple’s, goal of having a healthy genetically
related child.26,27
Finally, the policy of only male embryo transfer could
send a problematic message to society: Those male children,
as the first generation following an MRT, should take the
entire risk of this experimental procedure. Consider another
policy of only female embryo transfer: Such female children
should take an even greater risk, because mtDNA is ma-
ternally inherited by future offspring. Such gender-biased
uses of MRTs would be problematic. The clinical use of
MRTs should be considered after the potential risks were
sufficiently minimized through preclinical research, re-
gardless of the future child’s gender.
The aforementioned argument primarily focused on
prospective parents and children who benefit from MRTs.
Next, we consider gender issues relevant to the egg donors,
both for MRT research and clinical practice.28 Because
research and the clinical practice of MRTs require oocytes
donated by healthy third-party women, it is crucial to
properly consider the possible health risks to such donors.
As oocyte retrieval is practiced with the use of several
medications, hormonal injection, and transvaginal aspira-
tion, it has been argued that female donors may be finan-
cially compensated for such burden, distress, and potential
health risks.29 Importantly, egg donation could not only be
motivated by mere financial or altruistic objectives, but
also could be so by the aim of securing other goods, for
example, having a niece, nephew, or grandchild (as sug-
gested by father-to-son sperm donation30).
The short-term health risks of egg extraction are not so
high if well practiced. For example, the occurrence of se-
vere ovarian hyperstimulation syndrome is 0.2–1%.31
Nevertheless, there are no quality long-term studies about
the health risks that egg donation might impose on young
egg donors. Recently, Schneider et al. have raised the
question of whether breast cancer risk follows oocyte re-
trieval.32 Their question stems from four clinical cases
where young women donated eggs and then, after some
years, developed breast cancer. If MRTs are to move for-
ward in an ethical way then the appropriate measures
should be in place for making it clear in the egg donation
consent forms, regardless of jurisdiction, that there are no
known data about the long-term health risks of egg dona-
tion for young donors. This is of paramount importance
since otherwise the egg donor’s informed consent would be
defective (i.e., it wouldn’t be really autonomous). If egg
donation does take place then the egg donors should have
the option of close follow-up. Establishing local or national
(voluntarily) registries of egg donors would facilitate such
long-term observation.
In its current practice worldwide, oocyte donation has
also raised important ethical question with regard to ex-
ploitation and the commodification of eggs.13,33 Unlike
sperm produced in men, oocytes are no longer regenerated
in women after birth, thus decreasing the number of oocytes
with every ovulation until menopause. Moreover, financial
compensation may be arranged for egg donors, because
oocyte retrieval involves potential health risks, medical
costs, loss of time or wage, as addressed above. However,
the transaction of such precious reproductive cells at higher
prices has prompted profound concern in some countries.
This worry has been exacerbated when people from affluent
countries travel to developing areas to acquire oocytes for
reproductive purposes.
A policy of morally acceptable compensation for a lim-
ited number of oocyte donations per one individual would
help prevent the exploitation of women. A donor registry
would further protect them by ensuring the possibility of
long-term follow-up. Concerns over oocyte donation re-
quired for MRT would not become a substantive public
health issue if MRTs were authorized at least initially only
for rare and serious cases, although such restriction would
require additional argument in its favor.34 But even if this
were the case our recommendations regarding egg donation
would still stand given the amount of women that donate
their eggs for third party reproduction. The total amount of
risk to living donors could also be diminished or eradicated
if practitioners relied on other egg sources, such as those
from cadaveric donation.
Finally, several research articles published after the le-
galization in the UK highlighted the possibility that MST
and PNT may fail to prevent mitochondrial disease in off-
spring, especially if matching patient’s nDNA and donor’s
mtDNA haplotype is not meticulously considered, although
this is a heavily contested point.4,5,7,8 Of note, the report on
the first MST admitted that mtDNA haplotype of the oocyte
donor (L2c) was different from that of the patient (I).6
Matching patient’s nDNA and donor’s mtDNA make it
difficult to find appropriate egg donors for MRT, but can
potentially contribute to the prevention of mitonuclear
mismatch.
Legitimacy in the UK, the US, and Mexico
The UK already has a policy on compensation for oocyte
donors (up to £750 per donation cycle) and for an egg donor
registry system. It also intends to secure contact information
for children born from conception using donor gametes.35
The regulation of PGD for preventing genetic diseases on a
condition-by-condition basis has already been established in
the country.36 And, after nationwide discussions, the UK
determined that only licensed clinics can provide MRTs as
an option for range of limited cases, and they did not adopt
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the policy of male-only embryo transfer.37 Moreover, the
country decided to require physicians to prepare a follow-up
scheme for MRT conceived children, but allowed parents
not to consent to the follow-up of their child.38 Thus it is
unlikely that any significant socioethical problems will arise
regarding the use of MRTs in the UK, except with the status
of the egg donor and the policy of voluntary follow-up of the
resultant children.
In contrast, the cross-border case of an MST alerts us of
the possibility of its widespread use in an imperfect way in
the world because of different regulatory standards. In the
US, the American Society for Reproductive Medicine
(ASRM) issued guidelines on financial compensation of
oocyte donors,39 stating that ‘‘Total payments to donors in
excess of $5,000 require justification and sums above
$10,000 are not appropriate.’’ However, the ASRM guide-
lines are nonbinding policy by a professional society. Coun-
trywide states’ statutes on oocyte donation are either not
enacted or vary from state to state, excluding some states such
as Louisiana that prohibits the sale of human oocyte.40 At
federal level, oocyte donation is largely allowed. Therefore,
the possibility of ‘‘exploitation and commodification of eggs’’
is more likely to occur in the US.41 In addition, in the US
there are no national regulations regarding the use of PGD,
unlike the UK.42
Congress passed the Consolidated Appropriations Act
2016 Sec. 749 in the end of 2015 (still effective in Con-
solidated Appropriations Act 2017 Sec. 736), which prohibits
the FDA from spending federal budget to review applications
regarding clinical trials in which ‘‘a human embryo is in-
tentionally created or modified to include a heritable genetic
modification.’’43 And more recently, the US-based physician,
who performed the cross-border MST, established a company
to offer MST to treat infertility, outside of the US, for women
in their 40s.44 At this point in time, clinically offering MST
for treating infertility cannot be justified, because there is no
clear evidence to suggest that mtDNA mutations due to old
age are causative of infertility.45 Finally, on August 4, 2017
the FDA sent Dr. Zhang a strong worded letter pointing out
various regulation violations that Dr. Zhang’s team incurred
on when they carried out MST, and they also pointed out that
Zhang’s company ‘‘Darwin Life’’ kept on marketing MRTs
within the US even when they have said that they would stop
doing so.46
Mexico currently lacks national regulations pertaining to
assisted reproduction. This means that there are no national
regulations concerning oocyte donation or PGD.12,47 In
addition, although the legality of the first MST is contro-
versial, Mexico has no explicit federal regulations concern-
ing the regulation of human germline genetic modification or
human genetic engineering.11,12,48
Again, consider the process of the first MST case led by
Dr. Zhang. They performed MST at their clinic in the US
and then shipped the euploid embryo to their affiliated clinic
in Mexico, in which the embryo was transferred to a Jor-
danian woman. The FDA warned that if practitioners intend
the marketing of MRT in the US then they need to obtain a
valid biologics license (for embryos made through MST in
this case) and provide supporting data that should be ob-
tained after approved clinical research. However, the first
MST case was considered to be research, not marketing of
biologics. In addition, the Consolidated Appropriations Act
2016 does not prohibit private-funded research in which
oocytes are reconstituted by MST and fertilized but not used
for embryo transfer in the US. Meanwhile, Mexico has no
explicit regulations relevant to the clinical use of such
modified embryos. If the boy born through MST develops
any health problems, the Jordanian parent can institute a
civil action in a court in Mexico. However, the legal pro-
ceedings may go against the parents because the parents
declined the follow-up examination of their boy.
The regulatory situations surrounding reproductive med-
icine in the US and Mexico suggest that we cannot make an
overall national moral assessment of the clinical practice of
MRTs, and thus, a case-by-case assessment of the morality of
MRTs must be carried out. Advertisements on reproductive
tourism websites already present four clinics (in Albania,
Israel, Russia, and Spain) that offer ‘‘nuclear transfer’’ as an
available treatment.49 Such advertisements, as well as the
cross-border use of MST, urge us to respond to the unregu-
lated use of MRT in each country.
Conclusion
The initiation and appropriate use of MRT in a country
should require the premise that oocyte donation is morally
acceptable and appropriately regulated. The current state of
MST and PNT underscores the need for further research, as
well as long-term follow-up of such children, in addition to
the urgent need of long-term studies regarding possible
health risks to young egg donors. More preclinical research
is required to improve the safety and efficacy of MRT. The
UK adopted the policy of voluntary follow-up of children
born from MRTs. However, the follow-up should be con-
ducted in a child-centered manner, requiring the mandatory
follow-up for at least several years or until they are legally
competent to refuse it. It must be noted that troubles in the
family structure, such as divorce and parental death, may
make follow-up difficult. To respond to the likelihood of
the widespread use of MRT in the world, the public, pro-
fessionals, ethicists, and policy makers should consider the
appropriateness and regulation of MRT.
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